Eli Lilly used the American Diabetes Association’s annual meeting to announce that its investigational triple agonist retatrutide can treat the conditions obesity drives, beyond the excess weight itself. Detailed Phase 3 results from the TRIUMPH-1 program showed the once-weekly GIP, GLP-1 and glucagon agonist cut moderate-to-severe obstructive sleep apnea severity by up to 60.6% and knee osteoarthritis pain by up to 73.1%. Meanwhile, a companion diabetes trial, TRANSCEND-T2D-1, published…
